Charles Schwab’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Charles Schwab’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,596	Closed	-$85.9K	–	3616
2022 Q4	$85.9K	Buy	+13,596	New	+$75.3K	﹤0.01%	3281
2022 Q3	–	Sell	-12,327	Closed	-$78K	–	3568
2022 Q2	$78K	Buy	+12,327	New	+$41.5K	﹤0.01%	3314
2019 Q2	–	Sell	-7,620	Closed	-$320K	–	3283
2019 Q1	$320K	Hold	7,620	–	–	﹤0.01%	2925
2018 Q4	$317K	Hold	7,620	–	–	﹤0.01%	2918
2018 Q3	$368K	Buy	7,620 +1,445	+23%	+$72.4K	﹤0.01%	2946
2018 Q2	$293K	Buy	+6,175	New	+$343K	﹤0.01%	2976
2017 Q2	–	Sell	-7,075	Closed	-$252K	–	3155
2017 Q1	$252K	Buy	+7,075	New	+$243K	﹤0.01%	2880

Charles Schwab's FSTX Position: Q1 2023 in Review

Charles Schwab sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 13,596 shares — an estimated $85.9K sold.

Charles Schwab first reported a position in FSTX in Q1 2017 and held it in 7 quarters. The position peaked at $368K in Q3 2018. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

Charles Schwab reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Charles Schwab sold 13,596 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $85.9K.
Charles Schwab first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2017 and held it in 7 quarters.
Charles Schwab's F-star Therapeutics, Inc. Common Stock position peaked at $368K in Q3 2018.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Charles Schwab's 13F filing for Q1 2023, filed 12 May 2023.